Allergy & Immunology
Guideline | Antibiotic therapy in patients with suspected antibiotic allergy
17 Jul, 2023 | 13:59h | UTC
Guidelines | Management of atopic dermatitis in adults with topical therapies
14 Jul, 2023 | 12:48h | UTC
Impact of newborn screening on severe combined immunodeficiency survival: results from a 36-year longitudinal study
14 Jul, 2023 | 12:45h | UTCMeasuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Findings from a 36-year longitudinal study provide direct evidence that newborn screening for SCID has been the primary driver of improved survival in new-born babies in the USA and Canada since 2010.
Read the full article: https://t.co/TAAcPztpF9 pic.twitter.com/cOxvNNJmb9
— The Lancet (@TheLancet) July 12, 2023
Review | Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA): two sides of the same coin
7 Jul, 2023 | 16:01h | UTCHES and EGPA: Two Sides of the Same Coin – Mayo Clinic Proceedings
Podcast | Wisely ordering autoantibodies
28 Jun, 2023 | 13:09h | UTC#399 Wisely Ordering Autoantibodies – ACP IM2023 – The Curbsiders
Adrenaline auto-injector prescription for patients at risk of anaphylaxis: BSACI guidance for primary care
6 Jun, 2023 | 14:28h | UTC
RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils
1 Jun, 2023 | 12:20h | UTCDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live
Commentary on Twitter
Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count. Full trial results: https://t.co/9IWZr3YqsN
— NEJM (@NEJM) May 21, 2023
Guideline | Investigation and management of acute transfusion reactions
29 May, 2023 | 11:02h | UTC
RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events
15 May, 2023 | 13:10h | UTCPhase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh#pediatrics
— NEJM (@NEJM) May 10, 2023
Cohort Study | Autoimmune disorders’ incidence, prevalence & co-occurrence by age, sex, and socioeconomic status
8 May, 2023 | 13:14h | UTCIncidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK – The Lancet (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
Our latest research is out in @TheLancet today
We sought to answer:
1. Are autoimmune diseases on the rise as has been suggested?
2. Can we identify clues as to their causes (genetic or environmental)?
3. Do different autoimmune diseases cluster together & what might this mean? pic.twitter.com/noCpPpo8FU— Nathalie Conrad (@nathalie_conrad) May 6, 2023
Cohort Study | Idiopathic CD4 Lymphocytopenia linked to increased infection risk and cancer prevalence
5 May, 2023 | 15:16h | UTCReappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Idiopathic CD4 lymphocytopenia was initially described approximately 30 years ago as #HIV infections were emerging. In this report, longer-term characteristics of this syndrome are described. https://t.co/kV45SKmRQv#InfectiousDisease
— NEJM (@NEJM) May 3, 2023
RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis
3 May, 2023 | 15:04h | UTCCommentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live
Commentary on Twitter
The ECZTRA 6 trial showed that targeted IL-13 inhibition with tralokinumab was efficacious and well tolerated in adolescents with moderate-to-severe AD, suggesting that it is a valuable treatment option in this age group. https://t.co/h36BW4XThE
— JAMA Dermatology (@JAMADerm) April 19, 2023
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
24 Apr, 2023 | 13:40h | UTCImmediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)
See Tweet from one of the authors with infographic and link to free full text here
Identifying perioperative anaphylaxis in Japan: epidemiology, allergens, and diagnostic tools
17 Apr, 2023 | 13:10h | UTC
M-A | Timing of allergenic food introduction and risk of immunoglobulin E–mediated food allergy
11 Apr, 2023 | 14:32h | UTCNews Release: Earlier introduction of allergenic foods in children may prevent food allergies – Imperial College London
Commentary: Allergenic Food Introduction Led to Fewer Allergies, Higher Withdrawal Rate from Intervention – HCP Live
Related:
AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease
Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society
Commentary on Twitter
In this study, earlier introduction of multiple allergenic foods was associated with a reduced risk of food allergy but with significant rates of withdrawal from the intervention. https://t.co/lZFkQIH9q7
— JAMA Pediatrics (@JAMAPediatrics) March 27, 2023
RCT | Baricitinib + topical corticosteroids effective in kids with moderate-severe atopic dermatitis
4 Apr, 2023 | 13:39h | UTC
Cohort Study | Associations between fetal or infancy pet exposure and food allergies
3 Apr, 2023 | 13:26h | UTC
RCT | Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention
31 Mar, 2023 | 13:26h | UTCEfficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Hereditary angioedema is a rare disease associated with unpredictable, recurrent angioedema attacks that can be life-threatening.
New study data support the use of garadacimab as a potential prophylactic therapy in adolescents and adults: https://t.co/xlxoA3J3sh 🧵 pic.twitter.com/VqCOHnaQAp
— The Lancet (@TheLancet) March 6, 2023
Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis
21 Mar, 2023 | 13:23h | UTCTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University
Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay
Study | Public health policies should recommend introducing peanut products to infants at 4-6 months of age to prevent peanut allergy
20 Mar, 2023 | 13:33h | UTCCommentary: Expert reaction to research on giving peanut products to babies – Science Media Centre
Related study: Early Introduction of Allergenic Foods Can Prevent Food Allergies in High Risk Infants
Related Guidelines:
AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease
Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society
Commentary from the author on Twitter
Latest paper from #LEAPStudy is now published in @JACIonline. We have looked at what happens if peanut products are introduced into the infant diet at different ages across the whole population. https://t.co/zpOlrNHOSihttps://t.co/xDIgYjezyS
More details below. @GoAllergy 1/12 pic.twitter.com/jY5MvdJ2AZ— Graham Roberts (@ProfGRoberts) January 12, 2023
Cohort Study | Leukotriene-receptor antagonist use during pregnancy not linked to neuropsychiatric events in offspring
17 Mar, 2023 | 12:56h | UTCCommentary: In utero exposure to asthma medication not tied to risks of neurodevelopmental disorders – MDedge
International consensus statement on allergy and rhinology: allergic rhinitis
16 Mar, 2023 | 13:19h | UTC
Drug allergy | A 2022 practice parameter update
3 Mar, 2023 | 13:59h | UTCDrug allergy: A 2022 practice parameter update – The Journal of Allergy and Clinical Immunology
Antibiotic allergy de-labeling: a pathway against antibiotic resistance
23 Feb, 2023 | 13:12h | UTCAntibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance – Antibiotics
Related:
M-A: Most patients with allergy to Penicillin can be given Cefazolin
Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy
Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule
NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk
M-A | Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis
16 Feb, 2023 | 15:04h | UTCSummary: The article examined the prevalence Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) associated with antibiotics worldwide. The analysis included 38 studies involving 2,917 patients, which showed that 28% of SJS/TEN cases were associated with antibiotics. Among antibiotic-associated SJS/TEN, the sulfonamide class was associated with 32% of cases, followed by penicillins, cephalosporins, fluoroquinolones, and macrolides.
Article: Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis – JAMA Dermatology (free for a limited period)
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.